Mithril Resources Ltd (ASX: MTH) refers to its ASX Release dated 30 November 2018 which provided a website linkto an announcement prepared by Perth-based public unlisted company Corona Minerals Limited (“Scoping StudyAnnouncement”) regarding the outcomes of their Scoping Study for the Spargos Reward Gold Deposit.Mithril has been advised that Corona’s Scoping Study Announcement may contain a number of material deficienciesand as such should not be relied upon by investors or shareholders.Mithril’s original ASX Release was made to ensure compliance with ASX Listing Rules Continuous Disclosureprovisions following the placement of the Scoping Study Announcement on Corona’s website by Corona.Spargos Reward is located 30 kilometres west of Kambalda, WA and is held in a Joint Venture between Corona(65%) and Mithril (35%).
- Forums
- ASX - By Stock
- MTH
- Ann: Retraction of Spargos Reward Scoping Study ASX Release
Ann: Retraction of Spargos Reward Scoping Study ASX Release, page-3
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MTH (ASX) to my watchlist
|
|||||
Last
17.5¢ |
Change
0.005(2.94%) |
Mkt cap ! $17.51M |
Open | High | Low | Value | Volume |
17.5¢ | 18.0¢ | 17.5¢ | $67.15K | 382.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 79027 | 17.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
18.0¢ | 153912 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 79027 | 0.175 |
4 | 124305 | 0.170 |
2 | 85151 | 0.165 |
4 | 35187 | 0.160 |
2 | 39750 | 0.155 |
Price($) | Vol. | No. |
---|---|---|
0.180 | 153912 | 3 |
0.185 | 280 | 1 |
0.190 | 2500 | 1 |
0.195 | 90000 | 1 |
0.200 | 34750 | 3 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
SKS
SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
MTH (ASX) Chart |